Newsroom
Sorted by: Latest
-
HSBC Bank Plc UK Regulatory Announcement: Early Repurchase(s)
LONDON--(BUSINESS WIRE)-- ISIN XS2754075260 Issuer Name HSBC Bank Plc Paying Agent HSBC Bank plc Redemption Type Repurchase Currency USD O/S Balance 100,000.00 New Balance 0.00 Value Date 06-Jan-26 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Eurozone AlphaDEX UCITS ETF 05.01.2026 FEUZ IE00B8X9NY41 1,105,638.00 EUR 64,736,647.52 58.551 ...
-
Citibank UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: SANDWELL COMMERCIAL FINANCE NO.2 PLC GBP 21,700,000.00 MATURING: 30-Sep-2037 ISIN: XS0229031017 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 31-Dec-2025 TO 31-Mar-2026 HAS BEEN FIXED AT 6.15 PCT DAY BASIS: ACTUAL/365(PROP) INTEREST PAYABLE VALUE 31-Mar-2026 WILL AMOUNT TO: GBP 506.98 PER GBP 33,412.11 DENOMINATION ...
-
Nanobubbles Market Research Report 2026-2036 with Detailed Profiles of Over 55 Nanobubble Equipment Manufacturers Worldwide - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "The Global Nanobubbles Market 2026-2036" report has been added to ResearchAndMarkets.com's offering. The Global Nanobubbles Market Report 2026-2036 provides detailed analysis, revenue forecasts, and strategic insights into the rapidly evolving nanobubble industry from 2026 through 2036. This report delivers actionable intelligence for investors, manufacturers, end users, and stakeholders seeking to understand market dynamics, identify growth opportunities, and navi...
-
HSBC Bank Plc UK Regulatory Announcement: Early Repurchase(s)
LONDON--(BUSINESS WIRE)-- ISIN XS2754075427 Issuer Name HSBC Bank Plc Paying Agent HSBC Bank plc Redemption Type Repurchase Currency USD O/S Balance 50,000.00 New Balance 0.00 Value Date 06-Jan-26 ...
-
Citibank UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: SANDWELL COMMERCIAL FINANCE NO.2 PLC GBP 14,000,000.00 MATURING: 30-Sep-2037 ISIN: XS0229031280 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 31-Dec-2025 TO 31-Mar-2026 HAS BEEN FIXED AT 9.00 PCT DAY BASIS: ACTUAL/365(PROP) INTEREST PAYABLE VALUE 31-Mar-2026 WILL AMOUNT TO: GBP 741.78 PER GBP 33,412.11 DENOMINATION ...
-
DivcoWest Acquires Four-Building, Class A R&D Campus in San Jose, CA
SAN JOSE, Calif.--(BUSINESS WIRE)--DivcoWest, a DivCore Capital company, in a partnership with Grove Real Estate Partners, has purchased The Campus at Trimble, a 253,000 square foot R&D campus located at 375-441 West Trimble Road in North San Jose. Terms of the transaction, which was sourced and closed off-market, were not disclosed. Newmark represented the seller. “We are excited by the fundamentals underpinning high-quality R&D projects across Silicon Valley, particularly given the su...
-
Citibank UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: Corporacion Andina De Fomento USD 100,000,000.00 MATURING: 13-Jul-2026 ISIN: XS2649633463 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 14-Oct-2025 TO 13-Jan-2026 HAS BEEN FIXED AT 4.93 PCT DAY BASIS: ACTUAL/360 INTEREST PAYABLE VALUE 13-Jan-2026 WILL AMOUNT TO: USD 2,493.24 PER USD 200,000.00 DENOMINATION ...
-
Kashiv BioSciences fera des présentations lors de la 44e conférence annuelle J.P. Morgan Healthcare
PISCATAWAY, New Jersey--(BUSINESS WIRE)--Kashiv BioSciences, LLC (« Kashiv »), une société biopharmaceutique verticalement intégrée, annonce aujourd’hui que le Dr Sandeep Athalye, CEO mondial, et le Dr Paras Vasanani, responsable du développement commercial, seront présents à la 44e conférence annuelle J.P. Morgan Healthcare à San Francisco, en Californie, le mercredi 14 janvier 2026, à 11h00 PST. 44e conférence annuelle J.P. Morgan Healthcare – présentation de Kashiv BioSciences Date : mercred...
-
Kashiv BioSciences participará en la 44.a Conferencia Anual de J.P. Morgan Healthcare
PISCATAWAY, Nueva Jersey--(BUSINESS WIRE)--Kashiv BioSciences, LLC («Kashiv»), empresa biofarmacéutica integrada verticalmente, acaba de anunciar que el Dr. Sandeep Athalye, director ejecutivo global, y el Dr. Paras Vasanani, director de Desarrollo Empresarial, ofrecerán una ponencia en la 44.ª Conferencia Anual de J.P. Morgan Healthcare, que se celebrará en San Francisco, California, el miércoles 14 de enero de 2026, a las 11:00 (Hora Estándar del Pacífico). 44.a Conferencia Anual de J.P. Morg...